Orthofix TraumaJet
This article was originally published in The Gray Sheet
Executive Summary
Ultrahigh-pressure, fluidjet-based wound debridement system made by HydroCision for distribution by Orthofix gains FDA market go-ahead. The device removes contamination and dead and damaged tissue with minimal risk of spreading infection, requires less sterile fluid than conventional irrigation devices, and has a $100 mil. worldwide market potential, according to Orthofix. Over 1,000 surgeons worldwide have been trained during the last year